Tingting Mou

Tingting Mou

Auto-generated profile, based on publicly available information

Tingting Mou

Department of Psychiatry, The First Affiliated Hospital, Zhejiang University School of Medicine, 310003 Hangzhou, Zhejiang, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2025 in ALPHA PSYCHIATRY
Verified
Journal Article
Open access
PDF file
CXChenyue Xu
Chenyue Xu
LKLingzhuo Kong
Lingzhuo Kong
TMTingting Mou
Tingting Mou
ATAnying Tang
Anying Tang
SHShaohua Hu
Shaohua Hu
JLJianbo Lai
Jianbo Lai
Accumulating evidence highlights the role of Vitamin B12 (VitB12) in the pathophysiology of affective disorders. However, its influence on brain function and the underlying mechanisms remain incompletely understood. In humans, VitB12 is obtained solely from dietary sources, primarily animal-based foods. VitB12 deficiency leads to the accumulation of homocysteine, a known contributor to emotional and behavioral dysregulation. VitB12 plays a critical role in maintaining neuron stability, synapsis plasticity, and regulating neuroinflammation by modulating key bioactive factors. These processes help to alleviate hippocampal damage, mitigate blood-brain barrier disruption, reduce oxidative stress, and enhance both structural and functional connectivity—collectively contributing to resilience against affective disorders. VitB12 from both diet and microbial sources is essential to gut homeostasis. Within the gut lumen, it stabilizes gut microbial communities, promotes short-chain fatty acid (SCFA) production, and supports neurotransmitter metabolism (e.g., serotonin and dopamine) via its role in S-adenosyl-l-methionine biosynthesis. Crucially, VitB12, gut microbiota, SCFAs, intestinal mucosa, and vagal nerve signaling interact synergistically within the gut-brain axis (GBA) to maintain gut microenvironment stability, protect the gut-blood barrier, and suppress neuroinflammatory cascades, eventually reducing the susceptibility to affective disorders. This review synthesizes current evidence on the involvement of VitB12 in the GBA, its association with mood regulation, and its potential as a nutritional adjunct in managing affective disorders. By elucidating this integrative mechanism, we provide new insights into targeting the GBA to improve clinical outcomes in affective disorders.

5 October 2025 in Actas Españolas de Psiquiatría
Verified
Journal Article
Open access
PDF file
TMTingting Mou
Tingting Mou
JLJianbo Lai
Jianbo Lai
LKLingzhuo Kong
Lingzhuo Kong
Background: Dysregulation of coagulation function associated with antipsychotic treatment remains poorly understood. This study investigates the potential impact of paliperidone on serum D-dimer levels during the early stages of treatment. Methods: Nine patients diagnosed with first-episode schizophrenic spectrum disorder were assessed for serum D-dimer levels before and after a 2-week paliperidone regimen. Additionally, eight adult C57 mice in the experimental group (EG) received 3 mg/kg of paliperidone daily for 10 consecutive days, while eight mice in the control group (CG) were untreated. Venous blood was collected and analyzed for D-dimer at baseline, and on the 5th and 10th days in the EG, as well as on the 10th day for the CG. Results: No significant differences were observed in serum D-dimer levels before and after paliperidone treatment in the patient cohort. In animal experiments, compared to the CG on the 10th day, serum D-dimer levels in the EG on the 10th day showed no significant difference (p > 0.05), while the level in the EG on the 5th day was significantly lower (p < 0.05). Compared to its baseline, serum D-dimer levels within the EG on the 5th day was significantly decreased (p < 0.05). Conclusion: Short-term paliperidone treatment had minimal effects on serum D-dimer levels in both human participants and mice, though transient changes were noted early in treatment. Nonetheless, the potential for drug-induced coagulation disruption should be considered in clinical practice.